Clinical trial
A Randomized, Phase II Study for Premenopausal Metastatic or Locally Advanced Breast Cancer Patients: Capivasertib, Goserelin, Fulvestrant With/Without Durvalumab, Versus Goserelin, Fulvestrant, and Durvalumab, Versus Goserelin/ Fulvestrant.
NCT05720260 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase II Study for Premenopausal Metastatic or Locally Advanced Breast Cancer Patients: Capivasertib, Goserelin, Fulvestrant With/Without Durvalumab, Versus Goserelin, Fulvestrant, and Durvalumab, Versus Goserelin/ Fulvestrant.
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 17, 2023
- Completion date
- January 31, 2027
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
er positive breast cancer, metastatic breast cancer, premenopausal breast cancer